Follow Us:Respiratio 2020, 2021, 2022; 10, 11, 12 (1-2-3): 2830286
ULOGA TOCILIZUMABA U LEČENJU PACIJENATA OBOLELIH ZBOG
KOVID 19 PNEUMONIJE
Snežana Cvetković 1 , Ana Samardžić 1, Ljudmila Nagorni Obradović 1,5 
, Rada Mišković 4,5 ,
Tatjana Vujić 1 , Dolika Vasović 2 ,Milan Dragišić 3 , Jasmina Opačić 1 , Zlatan Bojić 1
Original Research
Naučni članak
Sažetak: Uvod: Koronavirusna bolest (COVID-19) je zarazna bolest uzrokovana virusom SARS-CoV-
2. Pandemija COVID-19 je nesumnjivo uticala na sve nacionalne zdravstvene sisteme na različitim
nivoima. Svrha studije je bila da se proceni uloga Tocilizumaba u lečenju pacijenta obolelih zbog
COVID-19 pneumonije
Metodologija: Retrospektivna, jednocentrična serija slučajeva od 46 hospitalizovanih pacijenata sa
potvrđenom COVID-19 pneumonijom koji su primili lek Tocilizumab. Praćeni su u periodu od novembra
2020 do januara 2021 godine u Klinici za pulmologiju Univerzitetskog Kliničkog centra Srbije.
Rezultati: Prosečna starost pacijenata je bila 59+ 14.2 godina, a 36 (78,26%) su bili muškarci.
Pacijenti su bili hospitalizovani na kliničkom odeljenju. Jedan ili više komorbiditeta je imalo 35
pacijenata (73,08%) i to : hipertenzija 23 (65.71 %), dijabetes 6 (17,14 %), kardiovaskularne bolesti 8
(22,85%) i astma 4 (11,42%) . Saturacija kiseonikom ispod 90% registrovano je kod 43 (91.48%)
pacijenata pulsnim oksimetrom. IL-6 je bio povišen kod 44 pacijenata (95.65%). U hemostazi povišen ddimer je registrovan kod 41 (89.13%) i fibrinogen kod 38 pacijenata (82,6%).
Zaključak: Statistički je značajna primena Tocilizumaba u regulisanju CRP i fibrinogena u
referetnim vredostima. Primena imunomodulatorne terapije je pokazala značajnu regresiju na kontrolnim
radiografiji pluća kod 39 (95.65%) pacijenata.
Literatura
|
1. Salvarani C, Dolci G, Massari M, et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med 2021; 181:24. |
|
|
|
|
|
2. Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med 2021; 384:20. |
|
|
|
|
|
3. Paola Toniati, Simone Piva, Marco Cattalini, Emirena Garrafa, Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy |
|
|
|
|
|
4. Mariette X, Hermine O, Tharaux PL, et al. Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial. JAMA Intern Med 2021; 181:1241. |
|
|
|
|
|
5. Saba Khurshid, Neelum Rehman, Saad Ahmed, Bilal Ahmad, Mustafa Khurshid , Anjum Muhammad , Fuad A. Siddiqi, Dure Nayab, Hasan Saleem, Zulqurnain Saleem : Early Fall in C-Reactive Protein (CRP) Level Predicts Response to Tocilizumab in Rapidly Progressing COVID-19: Experience in a Single-Arm Pakistani Center |
|
|
|
|
|
6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020; 323:1239. |
|
|
|
|
|
7. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020; 369:m1966. |
|
|
|
|
|
8. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel CoronavirusInfected Pneumonia. N Engl J Med 2020; 382:1199. |
|
|
|
|
|
9. Cunningham JW, Vaduganathan M, Claggett BL, et al. Clinical Outcomes in Young US Adults Hospitalized With COVID-19. JAMA Intern Med 2020. |
|
|
|
|
|
10. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID- 19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054. |
|
|
|
|
|
11. CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:382. |
|
|
|
|
|
12. Harrison SL, Fazio-Eynullayeva E, Lane DA, et al. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Med 2020; 17:e1003321. |
|
|
|
|
|
13. Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov 2020; 10:783. |
|
|
|
|
|
14. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395:514. |
|
|
|
|
|
15. Lowe KE, Zein J, Hatipoglu U, Attaway A. Association of Smoking and Cumulative Pack-Year Exposure With COVID-19 Outcomes in the Cleveland Clinic COVID-19 Registry. JAMA Intern Med 2021; 181:709. |
|
|
|
|
|
16. Lowe KE, Zein J, Hatipoglu U, Attaway A. Association of Smoking and Cumulative Pack-Year Exposure With COVID-19 Outcomes in the Cleveland Clinic COVID-19 Registry. JAMA Intern Med 2021; 181:709. |
|
|
|
|
|
17. Kompaniyets L, Goodman AB, Belay B, et al. Body Mass Index and Risk for COVID-19-Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death - United States, March-December 2020. MMWR Morb Mortal Wkly Rep 2021; 70:355. |
|
|
|
|
|
18. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol 2020; 5:802. |
|
|
|
|
|
19. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020; 26:1636. |
|
|
|
|
|
20. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020; 180:934. |
|
|
|
|
|
21. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382:1708. |
|
|
|
|
|
22. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323:1061. |
|
|
|
|
|
23. Moll M, Zon RL, Sylvester KW, et al. VTE in ICU Patients With COVID-19. Chest 2020; 158:2130. |
|
|
|
|
|
24. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46:1089. |
|
|
|
|
|
25. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191:145. |
|
|
|
|
|
26. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191:145. |
|
|
|
|
|
27. Liotta EM, Batra A, Clark JR, et al. Frequent neurologic manifestations and encephalopathyassociated morbidity in Covid-19 patients. Ann Clin Transl Neurol 2020; 7:2221. |
|
1 Klinika za pulmologiju, Univerzitetski klinički centar Srbije
2 Klinika za očne bolesti, Univerzitetski klinički centar Srbije
3 Klinika za ORL i MFH, Univerzitetski klinički centar Srbije
4 Klinika za alergologiju i imunologiju, Univerzitetski klinički centar Srbije
5 Medicinski fakultet, Univerziteta u Beogradu